This recent review article highlights the evolution of Teleport Pharmaceutical Founder Professor Robin Polt’s groundbreaking work in synthetic approaches of peptide glycosylation.
New methods and application approaches improve the pharmacokinetic profiles and membrane permeability of peptides which greatly improve peptide stability and peptide-membrane interactions per blood-brain barrier penetration.
Current application of this work is being developed for large scale manufacture of glycopeptide drugs and show great promise in clinical settings through the work of Apostol and Hay, U of A.